Jan 11, 2023 / 07:15PM GMT
David James Adlington - JPMorgan Chase & Co, Research Division - Head of Medical Technology and Services Equity Research
Good morning, everybody. I'm David Adlington. I head up the European medtech research team for JP. It's my pleasure to introduce David Endicott, CEO of Alcon. There will be a Q&A session afterwards. The company has asked me to remind you that they will not be making many specific comments around FY '23, given that they want to talk about that at their full year results in February. David, my pleasure. Over to you.
David J. Endicott - Alcon Inc. - CEO & Director
Thank you, and good morning. Let me start by giving a quick overview of Alcon. And just for those of you who may not be familiar with this, Alcon is a leader in -- really in a specialty market of ophthalmology. We -- in eye care broadly, it is a really, I would say, kind of dynamic and important and very specific market. And I think we benefit a great deal from markets that are quite resilient.
So when you look at health care and you look at priorities of government
Alcon AG at JPMorgan Healthcare Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers